About Stallergenes

Stallergenes worldwide

Stallergenes is present in almost 50 countries via 13 subsidiaries and has entered into numerous partnerships and distribution agreements.

With direct operations in 14 countries, Stallergenes now conducts around 85% of its business in Europe.

The Group policy of forming strategic partnerships has made it possible to develop links with pharmaceutical companies that are heavily established in their countries' markets. This policy has led Stallergenes to build its presence on new emerging markets such as China, South Korea, Russia and Latin America but also strategic markets like the United States and Japan.

An exclusive partnership opening the doors to Japan


In September 2010, Stallergenes entered into an exclusive partnership agreement with Shionogi & Co., Ltd., one of the leading Japanese laboratories.
This partnership is the first of its kind in Japan, and concerns two sublingual allergen immunotherapy tablet products : Actair® house dust mite tablets and Japanese cedar pollen tablets.  

On the map are mentioned: headquarters (in red), subsidiaries (in blue), distributors and partners (in black)